Who is Leem?

Leem is the French industry association which represents drug companies operating in France.

Representing and defending the pharmaceutical industry

Leem has over 260 member companies representing a total workforce of 98,690 employees (more than 3% of industrial employment in France) and a revenue of more than € 54.5 billion (of which half are exports).

The industry association provides its members with in-depth, quantified and well-reasoned studies and analyses on the major issues facing the industry and on current events.

On a national level, Leem acts as a champion and advocate for the pharmaceutical industry.

In this capacity, it participates in numerous official, ministerial and inter-ministerial committees.

Leem is a member of the French Federation of Healthcare Industries (FEFIS) and of the French Enterprise Movement (MEDEF). At international level, Leem is a member of the European Federation of Pharmaceutical Associations and Industries (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), to which Leem's Director General was appointed as Vice-President in May 2017.

Engaging in agreement-based policy with the State

Every three years since 1994, Leem has negotiated the agreement-based policy with the State for the price setting and regulation of medicines in France through a "framework agreement".

The latest policy, signed in January 2016, provides the government and pharmaceutical companies with a solid basis to address the issue of innovative treatment pricing.

As the interlocutor between industry and policy makers, Leem is the driving force behind proposals to promote France's attractiveness as an industrial hub and to pursue a healthcare policy geared towards patients' needs, while preserving the benefits delivered by innovative therapies as well as the healthcare spending control target.

Negotiating with social partners

Leem is the only pharmaceutical employers' association in France and, as such, engages in social policy work on behalf of the sector, negotiating, among other things, the collective agreement or minimum wage agreements with social partners.
Promoting and defending ethical standards

In its promotion of responsible conduct within the healthcare system, Leem is committed to a CSR policy that has been jointly developed by society and industry stakeholders. The first industry association to sign the Joint Statement of Transparency International France on Ethical and Responsible Lobbying (July 2015), Leem is working to ensure that pharmaceutical companies uphold the standards of professional ethics. Through the Conduct and Ethics Committee of the French Association of Pharmaceutical Companies (Codeem), which was set up in 2011, it provides ethical oversight, promotes awareness and proposes professional guidelines to its member companies (protection of whistleblowers, clarification on conflicts of interest, etc.) and has powers to impose sanctions when the rules of ethics are breached.